1. **NAME OF THE MEDICINAL PRODUCT**

Pyridoxine multichem, 50mg, tablets.

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each 50mg tablet contains 50mg of pyridoxine hydrochloride.

**Excipients with known effect**

Pyridoxine is lactose and gluten free.

For a full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

Pyridoxine multichem 50mg tablets are white, round, 8.7mm in diameter, biconvex, engraved with “APO” on one side and “PYR” over “50” on the other side. Each tablet contains 50mg pyridoxine hydrochloride and typically weighs 235mg.

4. **CLINICAL PARTICULARS**

4.1 **Therapeutic indications**

The prevention and management of vitamin B6 deficiency.

Treatment of sideroblastic anaemias, homocystinuria or primary hyperoxaluria.

Vitamin B6 dependency in infants.

Pyridoxine has been widely used in premenstrual syndrome despite controversy over its effectiveness.

4.2 **Dose and Method of administration**

**Dose**

In preventing vitamin deficiencies adequate dietary intake is preferred over supplementation whenever possible. An adequate human diet in most circumstances is one containing between 1 and 2 mg vitamin B6 daily.

Doses of up to 150mg daily have been used in general deficiency states.

Doses of up to 100mg daily from either the onset of symptoms or for 14 days prior to the start of menstruation have been used.

**Method of administration**

Higher doses of between 200-600mg daily have been used in the treatment of sideroblastic anaemias, with similar doses being used to treat certain metabolic disorders such as homocystinuria or primary hyperoxaluria. Lifelong supplementation may be required to prevent reoccurrence.
Some infants require IM or IV administration for seizures due to vitamin B6 dependency and some may require lifelong supplementation with oral doses of 2-100mg.

4.3 Contraindications
Hypersensitivity to pyridoxine hydrochloride.

4.4 Special warnings and precautions for use
Vitamin B6 is relatively nontoxic at normal doses however long-term administration of high doses (2-6g daily) is associated with the development of severe peripheral neuropathies. Concerns exist about the possibility of neurotoxicity occurring. There have been reports of doses of 500mg daily having a toxic effect.

4.5 Interaction with other medicines and other forms of interaction
Pyridoxine increases the peripheral metabolisation of levodopa. When levodopa is combined with carbidopa this effect is prevented.

Isoniazid, cycloserine, pyrazinamide and penicillamine may antagonise the effects of pyridoxine and lead to a secondary deficiency.

It has been reported that pyridoxine decreases serum concentrations of phenobarbitone. Patients taking oestrogens e.g. oral contraceptives have higher vitamin B6 requirements.

4.6 Fertility, pregnancy and lactation
Pregnancy
Daily dietary requirements may increase slightly during pregnancy. No adverse effects have been reported with the use of physiologic doses during pregnancy. However the use of high doses during pregnancy has been implicated in some cases of vitamin B6 dependent syndrome in infants. Vitamin B6 crosses the placenta and also appears in breast milk.

Lactation
Vitamin B6 is excreted in breast milk however no adverse effects have been reported with the use of physiologic doses during lactation.

4.7 Effects on ability to drive and use machines
Presumed to be safe or unlikely to produce an effect on the ability to drive or use machinery.

4.8 Undesirable effects
Nausea, headache, paresthesia, somnolence and low serum folic acid concentrations have been reported.

Vitamin B6 is relatively nontoxic at normal doses however long-term administration of high doses (2-6g daily) is associated with the development of severe peripheral neuropathies.

There have been reports of doses of 500mg daily having a toxic effect.
Transient dependency symptoms may occur upon withdrawal of therapy at a dose of 200mg/day for over 1 month. The significance of this is not known however for patients on large doses for long period of time withdrawal of therapy should probably be gradual.

**Reporting of suspected adverse reactions**
Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professional are asked to report any suspected adverse reactions [https://nzphvc.otago.ac.nz/reporting/](https://nzphvc.otago.ac.nz/reporting/).

4.9 **Overdose**
Sensory neuropathy can occur following long term administration of large doses. Withdrawal should be started but should probably be gradual to prevent the occurrence of transient dependency symptoms.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5. **PHARMACOLOGICAL PROPERTIES**

5.1 **Pharmacodynamic Properties**
Pharmacotherapeutic group: Vitamin preparations. ATC code: A11HA02

**Mechanism of Action**
Pyridoxine (vitamin B6) is a water-soluble vitamin involved principally in amino acid metabolism, but is also involved in carbohydrate and fat metabolism. It is also required for the formation of haemoglobin.

Pyridoxine deficiency is rare in humans because of its widespread distribution in foods.

Pyridoxine deficiency may be drug induced, and inadequate utilization of pyridoxine may result from certain inborn errors of metabolism. Pyridoxine deficiency may lead to sideroblastic anaemia, dermatitis, cheilosis and neurological symptoms such as peripheral neuritis and convulsions.

5.2 **Pharmacokinetic properties**
Pyridoxine is readily absorbed from the gastrointestinal tract after oral administration and converted to the active forms pyridoxal phosphate and pyridoxamine phosphate. They are stored mainly in the liver where there is metabolism to 4-pyridoxic acid and other inactive metabolites which are excreted in the urine. As the dose increases proportionally greater amounts are excreted unchanged in the urine. Vitamin B6 crosses the placenta and also appears in breast milk.

5.3 **Preclinical safety data**
Not applicable
6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients
Pyridoxine multichem tablet contains the following excipients:

- Microcrystalline Cellulose
- Croscarmellose sodium
- Calcium hydrogen phosphate
- Aerosil
- Magnesium Stearate

Pyridoxine multichem is lactose and gluten free.

6.2 Incompatibilities
Not applicable

6.3 Shelf life
4 years.

6.4 Special Precautions
Store below 30°C
Protect from heat, light and moisture. Keep the container tightly closed.

6.5 Nature and contents of container
HDPE Bottles of 100 or 500 tablets
Not all pack sizes maybe marketed.

6.6 Special precautions for disposal
No special requirements for disposal.
Any unused medicine or waste material should be disposed of in accordance with local requirements.

7. MEDICINE SCHEDULE
General Sale Medicine.

8. SPONSOR
Multichem NZ Ltd
Private Bag 93527
Takapuna
Auckland 0740
Telephone: (09) 488 0330
9. DATE OF FIRST APPROVAL
31 December 1969

10. DATE OF REVISION OF THE TEXT
11 November 2021

SUMMARY TABLE OF CHANGES

<table>
<thead>
<tr>
<th>Section</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole datasheet</td>
<td>Minor formatting changes.</td>
</tr>
<tr>
<td>8</td>
<td>Updated to new sponsor details.</td>
</tr>
</tbody>
</table>